Skip to main content

Table 3 Transcripts significantly up-regulated in metastasizing tumors in both cohorts

From: High expression of GEM and EDNRA is associated with metastasis and poor outcome in patients with advanced bladder cancer

 

Non-metastatic vs metastatic tumors

Lymph node metastasis vs non-metastatic tumors

Non-metastatic vs metastatic tumors

(Riester et al.)

Transcript

p-value

FC

p-value

FC

p-value

FC

COL6A2

0.0397

1.0967

0.7515

0.1176

0.0461

1.7263

LMCD1

0.0248

1.1631

0.0036

1.7576

0.0196

1.7212

FZD1

0.0287

1.5193

0.0878

1.1318

0.0055

1.0648

MITF

0.0364

1.6083

0.4593

-0.3003

0.0164

1.0783

EDNRA

0.0051

1.6613

0.0181

1.0262

0.0177

1.4840

EBF1

0.0211

1.7592

0.0168

1.8477

0.0149

1.0386

TPST1

0.0199

1.7953

0.1975

0.8709

0.0318

1.1064

AEBP1

0.0242

2.2697

0.0077

1.6563

0.0072

3.0447

PALLD

0.0344

2.3131

0.1163

0.9763

0.0104

1.4558

GEM

0.0121

2.3136

0.0000

3.2533

0.0219

1.5247

PXDN

0.0044

3.1464

0.0042

1.8611

0.0356

1.9232

KITLG

0.0110

3.3621

0.0537

1.6857

0.0323

1.1616

  1. FC = Log 2 fold change differences.
  2. Bold indicates significant p-values when comparing lymph node metastasis and non-metastatic tumors.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us